172 related articles for article (PubMed ID: 37085036)
1. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis.
Swystun LL; Michels A; Lillicrap D
J Thromb Haemost; 2023 Aug; 21(8):2007-2019. PubMed ID: 37085036
[TBL] [Abstract][Full Text] [Related]
2. The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.
Swystun LL; Notley C; Georgescu I; Lai JD; Nesbitt K; James PD; Lillicrap D
J Thromb Haemost; 2019 Apr; 17(4):681-694. PubMed ID: 30740857
[TBL] [Abstract][Full Text] [Related]
3. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
[TBL] [Abstract][Full Text] [Related]
4. The scavenger receptor SCARA5 is an endocytic receptor for von Willebrand factor expressed by littoral cells in the human spleen.
Swystun LL; Ogiwara K; Lai JD; Ojala JRM; Rawley O; Lassalle F; Notley C; Rengby O; Michels A; Nesbitt K; Tryggvason K; Lillicrap D
J Thromb Haemost; 2019 Aug; 17(8):1384-1396. PubMed ID: 31126000
[TBL] [Abstract][Full Text] [Related]
5. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity.
Swystun LL; Lai JD; Notley C; Georgescu I; Paine AS; Mewburn J; Nesbitt K; Schledzewski K; Géraud C; Kzhyshkowska J; Goerdt S; Hopman W; Montgomery RR; James PD; Lillicrap D
J Clin Invest; 2018 Aug; 128(9):4057-4073. PubMed ID: 30124466
[TBL] [Abstract][Full Text] [Related]
6. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
Ogiwara K; Swystun LL; Paine AS; Kepa S; Choi SJ; Rejtö J; Hopman W; Pabinger I; Lillicrap D
J Thromb Haemost; 2021 Mar; 19(3):654-663. PubMed ID: 33219619
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels.
Antoni G; Oudot-Mellakh T; Dimitromanolakis A; Germain M; Cohen W; Wells P; Lathrop M; Gagnon F; Morange PE; Tregouet DA
BMC Med Genet; 2011 Aug; 12():102. PubMed ID: 21810271
[TBL] [Abstract][Full Text] [Related]
8. The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms.
Sacco M; Lancellotti S; Branchini A; Tardugno M; Testa MF; Lunghi B; Bernardi F; Pinotti M; Giusti B; Castaman G; De Cristofaro R
J Thromb Haemost; 2022 Aug; 20(8):1818-1829. PubMed ID: 35596664
[TBL] [Abstract][Full Text] [Related]
9. Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice-Brief Report.
Ward SE; Guest T; Byrne C; Lopes P; O'Sullivan JM; Doherty D; O'Connell D; Gutierrez Llaneza S; Chion A; Fazavana J; Fallon PG; Preston RJS; Johnsen JM; Pipe SW; Turecek PL; O'Donnell JS;
Arterioscler Thromb Vasc Biol; 2023 Apr; 43(4):540-546. PubMed ID: 36727518
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
11. High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats.
Øie CI; Roepstorff K; Behrens C; Bøggild Kristensen J; Karpf DM; Bolt G; Gudme CN; Kjalke M; Smedsrød B; Appa RS
J Thromb Haemost; 2016 Sep; 14(9):1803-13. PubMed ID: 27378673
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
[TBL] [Abstract][Full Text] [Related]
13. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
14. Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
Lunghi B; Morfini M; Martinelli N; Branchini A; Linari S; Castaman G; Bernardi F
Haemophilia; 2023 Mar; 29(2):479-487. PubMed ID: 36533781
[TBL] [Abstract][Full Text] [Related]
15. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
Cao W; Trask AR; Bignotti AI; George LA; Doshi BS; Sabatino DE; Yada N; Zheng L; Camire RM; Zheng XL
J Thromb Haemost; 2023 Dec; 21(12):3477-3489. PubMed ID: 37726033
[TBL] [Abstract][Full Text] [Related]
16. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():679-691. PubMed ID: 37204745
[TBL] [Abstract][Full Text] [Related]
17. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
López-Fernández MF; Blanco-López MJ; Castiñeira MP; Batlle J
Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
[TBL] [Abstract][Full Text] [Related]
18. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.
Smith NL; Chen MH; Dehghan A; Strachan DP; Basu S; Soranzo N; Hayward C; Rudan I; Sabater-Lleal M; Bis JC; de Maat MP; Rumley A; Kong X; Yang Q; Williams FM; Vitart V; Campbell H; Mälarstig A; Wiggins KL; Van Duijn CM; McArdle WL; Pankow JS; Johnson AD; Silveira A; McKnight B; Uitterlinden AG; ; Aleksic N; Meigs JB; Peters A; Koenig W; Cushman M; Kathiresan S; Rotter JI; Bovill EG; Hofman A; Boerwinkle E; Tofler GH; Peden JF; Psaty BM; Leebeek F; Folsom AR; Larson MG; Spector TD; Wright AF; Wilson JF; Hamsten A; Lumley T; Witteman JC; Tang W; O'Donnell CJ
Circulation; 2010 Mar; 121(12):1382-92. PubMed ID: 20231535
[TBL] [Abstract][Full Text] [Related]
19. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
20. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels.
Rydz N; Swystun LL; Notley C; Paterson AD; Riches JJ; Sponagle K; Boonyawat B; Montgomery RR; James PD; Lillicrap D
Blood; 2013 Jun; 121(26):5228-37. PubMed ID: 23529928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
